Neurotech International Limited (ASX:NTI)

Australia · Delayed Price · Currency is AUD

0.0140

-0.0010 (-6.67%)

Jun 22, 2026, 4:10 PM AEST

-17.65% (1Y)

Market Cap	19.77M -18.1%
Revenue (ttm)	7.07M +8,687.8%
Net Income	-3.85M
EPS	-0.00
Shares Out	1.32B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	598,925
Open	0.0140
Previous Close	0.0150
Day's Range	0.0130 - 0.0140
52-Week Range	0.0100 - 0.0290
Beta	0.03
Analysts	n/a
Price Target	0.60 (+4,185.71%)
Earnings Date	Jul 24, 2026

About Neurotech International

Neurotech International Limited, a clinical-stage biopharmaceutical development company, engages in the research, design, development, and manufacture of medical devices and solutions in Australia. The company focuses on development and commercialization of NTI164 for multiple paediatric neurological disorders; and Mente, a clinically proven home therapy aimed at enhancing engagement and relaxation in autistic children exhibiting elevated delta band brain activity. It also engages in executing medical research projects; and developing technolog... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2016

Country Australia

Stock Exchange Australian Securities Exchange

Ticker Symbol NTI

Full Company Profile

Financial Performance

In fiscal year 2025, Neurotech International's revenue was 2.44 million, a decrease of -23.07% compared to the previous year's 3.18 million. Losses were -10.60 million, 109.1% more than in 2024.

Financial Statements